SDZXF (Sandoz Group AG) Land And Improvements : $80 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG Land And Improvements?

Sandoz Group AG's land and improvements for the quarter that ended in Dec. 2024 was $80 Mil.

Sandoz Group AG's quarterly land and improvements declined from Dec. 2023 ($71 Mil) to Jun. 2024 ($0 Mil) but then increased from Jun. 2024 ($0 Mil) to Dec. 2024 ($80 Mil).

Sandoz Group AG's annual land and improvements declined from Dec. 2022 ($101 Mil) to Dec. 2023 ($71 Mil) but then increased from Dec. 2023 ($71 Mil) to Dec. 2024 ($80 Mil).

Sandoz Group AG Land And Improvements Historical Data

The historical data trend for Sandoz Group AG's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG Land And Improvements Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

Dec24

Land And Improvements

101.00

71.00

80.00

Sandoz Group AG Semi-Annual Data
	Dec22	Jun23	Dec23	Jun24	Dec24
Land And Improvements	101.00	-	71.00	-	80.00

Sandoz Group AG Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Sandoz Group AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZXF) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

SDZNY:USA SDZz:UK 0SAN:UK D8Y:Germany SDZ:Switzerland

Address

Centralbahnstrasse 4, Basel, CHE, 4051

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.